Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 117 full-time employees. The company went IPO on 2007-06-25. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
How did NAGE's recent EPS compare to expectations?
The most recent EPS for Niagen Bioscience Inc is $, expectations of $.
How did Niagen Bioscience Inc NAGE's revenue perform in the last quarter?
Niagen Bioscience Inc revenue for the last quarter is $
What is the revenue estimate for Niagen Bioscience Inc?
According to of Wall street analyst, the revenue estimate of Niagen Bioscience Inc range from $ to $
What's the earning quality score for Niagen Bioscience Inc?
Niagen Bioscience Inc has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Niagen Bioscience Inc report earnings?
Niagen Bioscience Inc next earnings report is expected in
What are Niagen Bioscience Inc's expected earnings?
Niagen Bioscience Inc expected earnings is $, according to wall-street analysts.
Did Niagen Bioscience Inc beat earnings expectations?
Niagen Bioscience Inc recent earnings of $ expectations.